Sertindole
As of the edition of 20 October 2026, Sertindole is a small molecule: withdrawn from the market in 1998; acts on ADRA1A, ADRA1B and ADRA1D and 3 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Withdrawn from market, 1998
- Kind
- Small molecule
- Brand name
- Serdolect
- First approved
- 23 May 1996 (UK)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Lundbeck
- Withdrawn from market
- 1 January 1998 (in some regions)
- Registered trials
- 14, 3 stopped early
- Disease areas
- Mental health; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
4 company-target rows on route B and 1 company-target row on route A because of this drug.
Companies on route B for this drug
In the product4 company-target rows are on route B because of Sertindole.
See the 4 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Companies on route A for this drug
In the product1 company-target row is on route A because of Sertindole.
See the 1 company-target row on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 4 | 3 | 0 | 1 |
| Phase 3 | 6 | 5 | 0 | 1 |
| Phase 4 | 4 | 2 | 0 | 1 |
| All trials | 14 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Lundbeck | Originator and Lead sponsor of trials | 1996 to now |